A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at 13 weeks for adults with overweight or obesity, according to findings from ...

By Tarun Sai Lomte An expert editorial suggests that widely used diabetes and obesity drugs may help close the long-standing ...

Experts say that improving heart and metabolic health may be key to helping people with severe mental illness live longer, ...

Since their introduction 20 years ago, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolu­tionised the treatment of diabetes and obesity. Known for their immunomodulatory and ...

Bariatric surgery and GLP-1 drugs are associated with reductions in fat mass and a shift in body composition toward a higher ratio of fat-free mass to fat mass over 2 years.

HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for colorectal ...

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent ...

People who don’t get the weight loss results they’re after on a GLP-1 medication like Wegovy (semaglutide) may switch to a dual-agonist drug like Zepbound (tirzepatide) under the guidance of their ...

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

27.0 percent of the total pooled sample eligible, with higher eligibility seen in higher-income countries and for women.

Preclinical and Phase 1 study published in Nature Medicine describes clinical and mechanistic validation for OrsoBio's LXR ...

- ASC30 demonstrated placebo-adjusted weight loss of up to 7.7% in a recently completed 13-week U.S. Phase II study in participants with obesity or overweight, with better gastrointestinal ...